Nordic Level Group AB (9T2)

Overview

Dimerix Limited is a biopharmaceutical company based in Fitzroy, Australia, dedicated to the development and commercialization of innovative pharmaceutical products aimed at addressing unmet medical needs. The company is leveraging its expertise and technologies to develop treatments for various diseases, focusing on those with significant impact on patients' lives. With a commitment to improving patient outcomes, Dimerix Limited is actively engaged in advancing its pipeline of drug candidates through different stages of clinical trials.

Products and Services

• DMX-200 for Focal Segmental Glomerulosclerosis (FSGS)

  Currently in Phase 3 clinical trials, DMX-200 is Dimerix Limited’s flagship product designed to treat Focal Segmental Glomerulosclerosis, a rare disease that attacks the kidney’s filtering units, causing significant protein loss and chronic kidney disease. This product highlights Dimerix’s commitment to addressing severe renal diseases.

• DMX-200 for Diabetic Kidney Disease

  In Phase 2 of clinical trials, DMX-200 is also being tested for its effectiveness in treating diabetic kidney disease, another serious condition that deteriorates kidney function in patients with diabetes. This reflects the company's focus on leveraging its assets across multiple indications with substantial unmet needs.

• DMX-200 for ARDS Associated with COVID-19

  Dimerix has expanded the application of DMX-200 to include the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, recognizing the urgent need for effective treatments for complications arising from the pandemic. This initiative showcases the company’s agility in responding to emerging global health crises.

• DMX-700 for Chronic Obstructive Pulmonary Disease (COPD)

  DMX-700 is being developed as a therapeutic option for Chronic Obstructive Pulmonary Disease, a progressive lung disease that causes breathing difficulty. This project underscores Dimerix’s exploration into respiratory illnesses, expanding its portfolio into other areas with significant patient populations.

• Proprietary Receptor-HIT Assay Technology

  Beyond its drug development endeavors, Dimerix is also advancing its proprietary Receptor-HIT assay technology, a novel platform that enables the identification and characterization of receptor interactions. This technology underpins the company’s research and development activities, facilitating the discovery of new drug candidates and therapeutic targets.